dornase alfa dornase alfa dornase alfa, sold under the brand name pulmozyme, is used for the treatment of cystic fibrosis. it is a recombinant human deoxyribonuclease i (rhdnase), an enzyme which selectively cleaves dna. dornase alfa hydrolyzes the dna present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. it is produced in chinese hamster ovary cells. dornase alfaclinical datatrade namespulmozymeahfs/drugs.commonographmedlineplusa694002license data us dailymed: dornase alfa pregnancycategory au: b1 routes ofadministrationinhalationatc coder05cb13 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only / schedule d us: ℞-only in general: ℞ (prescription only) identifierscas number143831-71-4 ndrugbankdb00003 ychemspidernoneunii953a26oa1ykeggd03896comptox dashboard (epa)dtxsid801010888 echa infocard100.029.685 chemical and physical dataformulac1321h1999n339o396s9molar mass29254.04 g·mol−1 ny (what is this?) (verify) medical uses dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function. society and culture legal status dornase alfa is an orphan drug. research dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.